A phase I and pharmacokinetic study of rubitecan, an orally administered topoisomerase I (topo-I) inhibitor, combined with gemcitabine in patients with advanced cancer.

被引：0
|
作者：
Calvo, E
Rowinsky, EK
Tolcher, AW
Chu, QS
Beeram, M
Forero, L
Mettinger, KL
Eastham, E
Goetz, AD
Patnaik, A
机构：
[1] Canc Therapy & Res Ctr S Texas, San Antonio, TX USA
[2] SuperGen Inc, Dublin, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2099
引用
收藏
页码：151S / 151S
页数：1
相关论文
共 50 条
  • [41] Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II
    C J Twelves
    C Gardner
    A Flavin
    J Sludden
    I Dennis
    J de Bono
    P Beale
    P Vasey
    C Hutchison
    M A Macham
    A Rodriguez
    I Judson
    N M Bleehen
    British Journal of Cancer, 1999, 80 : 1786 - 1791
  • [42] Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C β-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer
    Rademaker-Lakhai, Jeany M.
    Beerepoot, Laurens V.
    Mehra, Niven
    Radema, Sandra A.
    van Maanen, Rianne
    Vermaat, Joost S.
    Witteveen, Els O.
    Visseren-Grul, Carla M.
    Musib, Luna
    Enas, Nathan
    van Hal, Gertjan
    Beijnen, Jos H.
    Schellens, Jan H. M.
    Voest, Emile E.
    CLINICAL CANCER RESEARCH, 2007, 13 (15) : 4474 - 4481
  • [43] Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer
    LoRusso, Patricia M.
    Jones, Suzanne F.
    Koch, Kevin M.
    Arya, Nikita
    Fleming, Ronald A.
    Loftiss, Jill
    Pandite, Lini
    Gadgeel, Shirish
    Weber, Barbara L.
    Burris, Howard A., III
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (18) : 3051 - 3056
  • [44] Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1–5 of a 3-weekly cycle in patients with advanced solid tumours
    M J A de Jonge
    S Kaye
    J Verweij
    C Brock
    S Reade
    M Scurr
    L van Doorn
    C Verheij
    W Loos
    C Brindley
    P Mistry
    M Cooper
    I Judson
    British Journal of Cancer, 2004, 91 : 1459 - 1465
  • [45] Phase I evaluation of paclitaxel poliglumex (PPX) administered weekly for patients with advanced cancer.
    Takimoto, CH
    Schwartz, G
    Romero, O
    Patnaik, A
    Tolcher, A
    Garrison, M
    Oldham, FB
    Bernareggi, A
    Rowinsky, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 145S - 145S
  • [46] Phase I evaluation of paclitaxel poliglumex (PPX) administered weekly for patients with advanced cancer.
    Takimoto, CH
    Verschraegen, C
    Young, D
    Oldham, FB
    Bernareggi, A
    Rowinsky, EK
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9118S - 9118S
  • [47] A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors
    Delaunoit, Thierry
    Burch, Patrick A.
    Reid, Joel M.
    Camoriano, John K.
    Kobayash, Tomowo
    Braich, Theodore A.
    Kaur, Judith S.
    Rubin, Joseph
    Erlichman, Charles
    INVESTIGATIONAL NEW DRUGS, 2006, 24 (04) : 327 - 333
  • [48] A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors
    Thierry Delaunoit
    Patrick A. Burch
    Joel M. Reid
    John K. Camoriano
    Tomowo Kobayash
    Theodore A. Braich
    Judith S. Kaur
    Joseph Rubin
    Charles Erlichman
    Investigational New Drugs, 2006, 24 : 327 - 333
  • [49] Phase I dose-escalation and pharmacokinetic study of antrubicin in patients with recurrent advanced lung cancer.
    Okamoto, I
    Hamada, A
    Matsunaga, Y
    Sasaki, JI
    Fujii, S
    Uramoto, H
    Yamagata, H
    Mori, I
    Kishi, H
    Semba, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 151S - 151S
  • [50] Phase I and pharmacological study of orally administered indibulin in advanced solid tumors
    Oostendorp, R. L.
    Witteveen, P. O.
    Schwartz, B.
    Beijnen, J. H.
    Voest, E. E.
    Schellens, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345